Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Chief Operating Officer | September 15, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 235,478 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 906 · Balance 235,478 F1: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 15, 2026 23:11 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 906 | $95.71 | $86,713.26 |
DisclosureSEC source: 0000907654-26-000094 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,478 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 22:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000088 · form4.xml · derivative · entry 4 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,996 Underlying: Common Stock · 5,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 22:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 4,000 | $92.01 | $368,053.60 |
DisclosureSEC source: 0000907654-26-000088 · form4.xml · nonDerivative · entry 3 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,384 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.60 to $92.59, inclusive. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 22:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 1,000 | $91.05 | $91,047.60 |
DisclosureSEC source: 0000907654-26-000088 · form4.xml · nonDerivative · entry 2 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 240,384 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.51 to $91.49, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 22:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 5,000 | $7.80 | $39,000.00 |
DisclosureSEC source: 0000907654-26-000088 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:58 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000069 · form4.xml · derivative · entry 5 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,996 Underlying: Common Stock · 5,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:58 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 500 | $95.47 | $47,736.00 |
DisclosureSEC source: 0000907654-26-000069 · form4.xml · nonDerivative · entry 4 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,384 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.40 to $95.51, inclusive. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:58 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,263 | $94.75 | $214,409.75 |
DisclosureSEC source: 0000907654-26-000069 · form4.xml · nonDerivative · entry 3 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.38 to $95.19, inclusive. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:58 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,237 | $93.85 | $209,932.83 |
DisclosureSEC source: 0000907654-26-000069 · form4.xml · nonDerivative · entry 2 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,147 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.29 to $94.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:58 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 5,000 | $7.80 | $39,000.00 |
DisclosureSEC source: 0000907654-26-000069 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:51 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 600 | $69.69 | $41,814.00 |
DisclosureSEC source: 0000907654-26-000061 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,384 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · derivative · entry 8 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,996 Underlying: Common Stock · 5,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 100 | $68.48 | $6,848.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 7 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,984 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 200 | $67.16 | $13,431.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 6 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,084 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.11 to $67.20, inclusive. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 400 | $66.06 | $26,422.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 5 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,284 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.85 to $66.23, inclusive. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 300 | $65.10 | $19,530.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 4 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,684 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.85 to $65.28, inclusive. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 1,800 | $64.15 | $115,467.84 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 3 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,984 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.59 to $64.55, inclusive. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,200 | $62.58 | $137,685.46 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 2 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,784 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.33 to $62.83, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 5,000 | $7.80 | $39,000.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:08 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 600 | $41.30 | $24,780.00 |
DisclosureSEC source: 0000907654-26-000031 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,984 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:47 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000022 · form4.xml · derivative · entry 4 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,996 Underlying: Common Stock · 5,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:47 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,675 | $33.81 | $90,435.60 |
DisclosureSEC source: 0000907654-26-000022 · form4.xml · nonDerivative · entry 3 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,584 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.66 to $34.33, inclusive. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:47 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,325 | $33.28 | $77,386.00 |
DisclosureSEC source: 0000907654-26-000022 · form4.xml · nonDerivative · entry 2 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 240,259 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.66 to $33.64, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:47 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 5,000 | $7.80 | $39,000.00 |
DisclosureSEC source: 0000907654-26-000022 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0000907654-26-000017 · form4.xml · derivative · entry 2 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-01-22 F2 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000017 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,584 F1 · shares: The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 01:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000002 · form4.xml · derivative · entry 5 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,996 Underlying: Common Stock · 5,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 01:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 1,108 | $29.75 | $32,966.99 |
DisclosureSEC source: 0000907654-26-000002 · form4.xml · nonDerivative · entry 4 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,084 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.56 to $29.92, inclusive. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 01:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 3,144 | $29.08 | $91,431.92 |
DisclosureSEC source: 0000907654-26-000002 · form4.xml · nonDerivative · entry 3 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,192 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.55 to $29.50, inclusive. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 01:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 8,748 | $28.17 | $246,396.17 |
DisclosureSEC source: 0000907654-26-000002 · form4.xml · nonDerivative · entry 2 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.55 to $28.52, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 01:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 5,000 | $7.80 | $39,000.00 |
DisclosureSEC source: 0000907654-26-000002 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 01:26 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $11.80 | $0.00 |
DisclosureSEC source: 0001062993-25-012406 · form4.xml · derivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on July 1, 2026, and as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.